Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAG1 | P54619 | 2/20 | 0.43 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.43 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.43 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.41 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.41 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.41 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2760502 | 0.79 | PRKAG1 (0.66) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL11026592 | 0.73 | PRKAG1 (0.50) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL46898 | 0.73 | PRKAG1 (0.65) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL47177 | 0.73 | PRKAG1 (0.50) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL47268 | 0.72 | PRKAG1 (0.80) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL2615611 | 0.66 | MEN1 (0.39) | ACHEBCHE | |
| SCHEMBL2615617 | 0.66 | STAT3 (0.39) | — | |
| SCHEMBL46890 | 0.66 | PRKAG1 (0.71) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL2740542 | 0.65 | PRKAG1 (0.64) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL47174 | 0.65 | PRKAG1 (0.61) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004218-A1 | NOVEL TETRAHYDRO-QUINOLINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004218-A1 | NOVEL TETRAHYDRO-QUINOLINE DERIVATIVES | GPR119, PRKAB1, PRKAG1 | PRKAG1 3/4885PRKAA1 5/4885PRKAB1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.